ABMC Announces Expansion of Sales of Its Rapid Drug Screen(R) in Spain.

--ABMC Receives NSAI Certificate of Registration of Quality System ISO 13485:2003--

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ: ABMC) has announced today that they have received an initial order of 80,000 units for its Rapid Drug Screen (RDS[R]) from Diagnosticos Rapidos De EspaEa of Sevilla, Spain, ABMC's distributor in Spain since June 2004. The value of the order exceeds $400,000 (USD).

Diagnosticos Rapidos, will launch a sales program in December with a television and radio campaign. Jose Maria Reyes Dorado, president of Diagnosticos Rapidos, has forecasted sales of between 500,000 and 975,000 units for the first year of the project.

The RDS, ABMC's original one-step lateral flow immunoassay test for the simultaneous detection of 2 to 10 drugs of abuse in urine, is FDA-cleared for professional use and CE Marked. Dorado forecasts that 75% of the tests sold will detect 5 drugs, with the remaining 25% detecting 8.

ABMC Chief Executive Officer Stan Cipkowski stated, "We have been working very closely with Jose Maria and his associates at Diagnosticos Rapidos De EspaEa for over two years. The progress they have made in their current markets for our RDS is impressive and we expect to see them succeed in other markets as well."

In a related announcement, the Company reported that they have recently received the NSAI Certificate of Registration of Quality System ISO 13485:2003. ISO 13485:2003 is the most comprehensive ISO quality standard specific to medical devices. Requirements for this standard include design controls, process controls, special processes, traceability, record retention, and regulatory actions - all critical for the medical device industry.

Cipkowski noted, "This ISO certification gives our customers added confidence that ABMC will meet or exceed their quality expectations, and is evidence of ABMC's commitment to all of our customers, including our customers outside of the United States."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One[R], Rapid TEC[R], RDS InCup[R] and Rapid TOX[TM] products test for the presence or absence of drugs of abuse in urine, while OralStat[R] tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader[TM] is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.